Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs

New England Journal of Medicine

Volumn 338, Issue 11, 1998, Pages 727-734

  Hawkey, Christopher J ^a   Karrasch, Jeffrey A ^b   Szczepañski, Leszek ^c   Walker, Donald G ^d   Barkun, Alan ^e   Swannell, Anthony J ^f   Yeomans, Neville D ^g  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b Peninsula Specialist Centre   (Australia)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d Sunshine Coast Day Surgery   (Australia)

^e MONTREAL GENERAL HOSPITAL   (Canada)

^f NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; KETOPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; UREASE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; ENDOSCOPY; FEMALE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; STOMACH EROSION; STOMACH ULCER; TREATMENT OUTCOME; ULCER HEALING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; DUODENAL ULCER; DYSPEPSIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MISOPROSTOL; OMEPRAZOLE; PROGNOSIS; PROTON PUMPS; RECURRENCE; REMISSION INDUCTION; STOMACH ULCER;

EID: 0032510378     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199803123381105     Document Type: Article

References (44)

1. Paakkari H. Epidemiological and financial aspects of the use of non-steroidal anti-inflammatory analgesics. Pharmacol Toxicol 1994;75:Suppl 2: 56-9.
2. Huang J, Hunt RH. A clinician's view of strategies for preventing NSAID-induced gastrointestinal ulcers. Inflammopharmacology 1996;4:17-30.
3. Wolfe F, Kleinheksel SM, Spitz PW, et al. A multicenter study of hospitalization in rheumatoid arthritis: frequency, medical-surgical admissions, and charges. Arthritis Rheum 1986;29:614-9.
4. Hazleman BL. Incidence of gastropathy in destructive arthropathies. Scand J Rheumatol Suppl 1989;78:1-4.
5. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990;300:278-84. [Erratum, BMJ 1990;300:764.]
6. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.
7. Henry D, Lim LL-Y, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
8. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
9. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
10. Fries JR NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl 1991;28:6-10.
11. McCarthy DM. Nonsteroidal antiinflammatory drug-induced ulcers: management by traditional therapies. Gastroenterology 1989;96:Suppl: 662-74.
12. Elliott SL, Yeomans ND, Buchanan RRC, Smallwood RA. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers: a placebo-controlled trial. Scand J Rheumatol 1994;23:171-6.
13. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988;2:1277-80.
14. Walt RP. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 1992;327:1575-80.
15. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
16. Scheiman JM. Pathogenesis of gastroduodenal injury due to nonsteroidal antiinflammatory drugs: implications for prevention and therapy. Semin Arthritis Rheum 1992;21:201-10.
17. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991;324:1716-25. [Erratum, N Engl J Med 1991;325:747]
18. Davenport HW. Gastric mucosal injury by fatty and acetylsalicylic acids. Gastroenterology 1964;46:245-53.
19. Chvasta TE, Cooke AR. The effect of several ulcerogenic drugs on the canine gastric mucosal barrier J Lab Clin Med 1972;79:302-15.
20. McCormack K, Brune K. Classical absorption theory and the development of gastric mucosal damage associated with the non-steroidal anti-inflammatory drugs. Arch Toxicol 1987;60:261-9.
21. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989;86:449-58.
22. Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut 1990;31:514-7
23. Scheiman JM, Behler EM, Loeffler KM, Elta GH. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994;39;97-103.
24. Walan A, Bader J-P, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989;320:69-75.
25. Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997;112:1817-22.
26. EEC note for guidance: good clinical practice for trials on medicinal products in the European community. Pharmacol Toxicol 1990;67:361-72.
27. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gas troduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297:1017-21.
28. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989;34:424-8.
29. Cullen DJE, Hawkey GM, Humphries H, et al. Role of non-steroidal anti-inflammatory drugs and Helicobacter pylori in bleeding peptic ulcer Gastroenterology 1994;106:Suppl:A66. abstract.
30. Cullen DJE, Hawkey GM, Greenwood DC, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal antiinflammatory drugs. Gut 1997;41:459-62.
31. Hudson N, Balsitis M, Filipowicz F, Hawkey CJ. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:748-51.
32. Hunt SM, McKenna SP, Williams J. Reliability of a population survey tool for measuring perceived health problems: a study of patients with osteoarthrosis. J Epidemiol Community Health 1981;35:297-300.
33. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NIC, Mattson ME, Furberg CD, Elinson J. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing, 1984:170-83.
34. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995;30:1046-52.
35. Ekström P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study. Scand J Gastroenterol 1996;31:753-8.
36. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for NSAID users. Aliment Pharmacol Ther (in press).
37. Bardhan KD, Bjarnason I, Scott DL, et al. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol 1993;32:990-5.
38. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
39. Labenz J, Tillenburg B, Peitz U, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997;92:576-81.
40. Verdú EF, Armstrong D, Idström J-P, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:743-8.
41. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996;91:2080-6.
42. Jensen DM, Cheng S, Kovacs TOG, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med 1994;330:382-6.
43. Penston JG, Wormsley KG. Nine years of maintenance treatment with ranitidine for patients with duodenal ulcer disease. Aliment Pharmacol Ther 1992;6:629-45.
44. Shallcross TM, Heatley RV. Effect of non-steroidal anti-inflammatory drugs on dyspeptic symptoms. BMJ 1990;300:368-9.